Literature DB >> 29294018

Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.

Rory D de Vries1, Nella J Nieuwkoop1, Fiona R M van der Klis2, Marion P G Koopmans1, Florian Krammer3, Guus F Rimmelzwaan1.   

Abstract

Influenza A virus (IAV) and influenza B virus (IBV) cause substantial morbidity and mortality during annual epidemics. Two distinct lineages of IBV are distinguished, based on variation in hemagglutinin (HA): B/Victoria/2/87-like (B/Vic) and B/Yamagata/16/88-like (B/Yam). Here, we show that, in humans, primary IBV infection with either lineage induces HA-specific antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. IBV infection induced antibodies specific to the HA head and stalk, but only HA stalk-specific antibodies mediated ADCC efficiently and displayed cross-reactivity with IBV of both lineages. This corresponds to recent findings that 2 points of contact between the effector and target cell (ie, HA and sialic acid, respectively, and the fragment crystallizable [Fc] domain and Fcγ receptor IIIα, respectively) are required for efficient ADCC activity and that antibodies specific for the receptor-binding site located in the head domain of HA therefore fail to mediate ADCC. Potentially, ADCC-mediating antibodies directed to the HA stalk of IBV contribute to cross-protective immunity to IBV of both lineages.
© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Influenza B virus; antibodies; antibody-dependent cellular cytotoxicity; hemagglutinin; natural killer cells

Mesh:

Substances:

Year:  2017        PMID: 29294018      PMCID: PMC5853962          DOI: 10.1093/infdis/jix546

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  42 in total

1.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

Authors:  David J DiLillo; Peter Palese; Patrick C Wilson; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

Review 2.  Influenza B viruses: not to be discounted.

Authors:  Carolien E van de Sandt; Rogier Bodewes; Guus F Rimmelzwaan; Rory D de Vries
Journal:  Future Microbiol       Date:  2015-09-11       Impact factor: 3.165

3.  Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.

Authors:  Mary Dawn T Co; Masanori Terajima; Stephen J Thomas; Richard G Jarman; Kamonthip Rungrojcharoenkit; Stefan Fernandez; In-Kyu Yoon; Darunee Buddhari; John Cruz; Francis A Ennis
Journal:  Viral Immunol       Date:  2014-08-20       Impact factor: 2.257

4.  Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands.

Authors:  R Bodewes; G de Mutsert; F R M van der Klis; M Ventresca; S Wilks; D J Smith; M Koopmans; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  Clin Vaccine Immunol       Date:  2011-01-05

5.  Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact.

Authors:  Paul E Leon; Wenqian He; Caitlin E Mullarkey; Mark J Bailey; Matthew S Miller; Florian Krammer; Peter Palese; Gene S Tan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-19       Impact factor: 11.205

6.  Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials.

Authors:  W E P Beyer; A M Palache; M Boulfich; A D M E Osterhaus
Journal:  Vaccine       Date:  2017-06-24       Impact factor: 3.641

7.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

8.  Exploration of the emergence of the Victoria lineage of influenza B virus.

Authors:  J-M Chen; Y-J Guo; K-Y Wu; J-F Guo; M Wang; J Dong; Y Zhang; Z Li; Y-L Shu
Journal:  Arch Virol       Date:  2006-11-02       Impact factor: 2.574

Review 9.  Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Curr Opin Virol       Date:  2013-08-24       Impact factor: 7.090

10.  Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody.

Authors:  Ning Chai; Lee R Swem; Mike Reichelt; Haiyin Chen-Harris; Elizabeth Luis; Summer Park; Ashley Fouts; Patrick Lupardus; Thomas D Wu; Olga Li; Jacqueline McBride; Michael Lawrence; Min Xu; Man-Wah Tan
Journal:  PLoS Pathog       Date:  2016-06-28       Impact factor: 6.823

View more
  16 in total

1.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

2.  One Step Forward in the Road Toward a Universal Influenza Vaccine.

Authors:  Octavio Ramilo; Rosa Rodriguez-Fernandez; Asuncion Mejias
Journal:  J Infect Dis       Date:  2017-12-27       Impact factor: 5.226

3.  Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.

Authors:  James D Allen; Hyesun Jang; Joshua DiNapoli; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

4.  Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.

Authors:  Michael J Moser; Yasuko Hatta; Claudia Gabaglia; Adriana Sanchez; Peter Dias; Sally Sarawar; Yoshihiro Kawaoka; Masato Hatta; Gabriele Neumann; Pamuk Bilsel
Journal:  Vaccine       Date:  2019-07-04       Impact factor: 3.641

5.  Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.

Authors:  Rory D de Vries; Arwen F Altenburg; Nella J Nieuwkoop; Erwin de Bruin; Stella E van Trierum; Mark R Pronk; Mart M Lamers; Mathilde Richard; David F Nieuwenhuijse; Marion P G Koopmans; Joost H C M Kreijtz; Ron A M Fouchier; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2018-07-13       Impact factor: 5.226

Review 6.  Influenza B: Prospects for the Development of Cross-Protective Vaccines.

Authors:  Liudmila M Tsybalova; Liudmila A Stepanova; Edward S Ramsay; Andrey V Vasin
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

7.  Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay.

Authors:  Veronika Chromikova; Jessica Tan; Sadaf Aslam; Arvind Rajabhathor; Maria Bermudez-Gonzalez; Juan Ayllon; Viviana Simon; Adolfo García-Sastre; Bruno Salaun; Raffael Nachbagauer; Florian Krammer
Journal:  Vaccine       Date:  2020-01-17       Impact factor: 3.641

8.  Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes.

Authors:  Alec W Freyn; Julianna Han; Jenna J Guthmiller; Mark J Bailey; Karlynn Neu; Hannah L Turner; Victoria C Rosado; Veronika Chromikova; Min Huang; Shirin Strohmeier; Sean T H Liu; Viviana Simon; Florian Krammer; Andrew B Ward; Peter Palese; Patrick C Wilson; Raffael Nachbagauer
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-23       Impact factor: 11.205

Review 9.  The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.

Authors:  Oliver Ringel; Vincent Vieillard; Patrice Debré; Jutta Eichler; Hildegard Büning; Ursula Dietrich
Journal:  Viruses       Date:  2018-04-15       Impact factor: 5.048

Review 10.  NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?

Authors:  Florian Krammer; Ron A M Fouchier; Maryna C Eichelberger; Richard J Webby; Kathryn Shaw-Saliba; Hongquan Wan; Patrick C Wilson; Richard W Compans; Ioanna Skountzou; Arnold S Monto
Journal:  mBio       Date:  2018-04-03       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.